menu
    • menu
    [{"orgOrder":0,"company":"Senores Pharmaceuticals","sponsor":"Seton Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Butalbital","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Senores Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Senores Pharmaceuticals \/ Senores Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Senores Pharmaceuticals \/ Senores Pharmaceuticals"},{"orgOrder":0,"company":"Senores Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Nicardipine Hydrochloride","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Senores Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Senores Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Senores Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Senores Pharmaceuticals","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ivermectin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Senores Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Senores Pharmaceuticals \/ Senores Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Senores Pharmaceuticals \/ Senores Pharmaceuticals"},{"orgOrder":0,"company":"Senores Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Metoprolol Tartrate","moa":"||Beta adrenoceptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Senores Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Senores Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Senores Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Senores Pharmaceuticals","sponsor":"Breckenridge Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Senores Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Senores Pharmaceuticals \/ Senores Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Senores Pharmaceuticals \/ Senores Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Senores Pharmaceuticals

    Menu

    Senores Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Senores Pharmaceuticals

                            India arrow
                            BePharma
                            Not Confirmed

                            Senores Pharmaceuticals

                            India arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Roflumilast

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved FDF

                            Recipient : Breckenridge Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Senores Pharma Gains After Arm Inks Pact to Acquire Roflumilast Tablets

                            Details : Senores acquire the USFDA-approved abbreviated new drug application for Roflumilast, indicated as a treatment to reduce the risk of COPD exacerbations, from Breckenridge.

                            Product Name : Roflumilast-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 21, 2025

                            Lead Product(s) : Roflumilast

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Breckenridge Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Senores Pharmaceuticals

                            India arrow
                            BePharma
                            Not Confirmed

                            Senores Pharmaceuticals

                            India arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Metoprolol Tartrate,Hydrochlorothiazide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Senores Pharma Gets Final Approval for Metoprolol Tartrate and Hydrochlorothiazide Tablets

                            Details : A combination tablet of metoprolol tartrate, a beta adrenoceptor blocker, and hydrochlorothiazide, a thiazide diuretic, has been approved for hypertension.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 10, 2025

                            Lead Product(s) : Metoprolol Tartrate,Hydrochlorothiazide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Senores Pharmaceuticals

                            India arrow
                            BePharma
                            Not Confirmed

                            Senores Pharmaceuticals

                            India arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : Dr. Reddy\'s Laboratories

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Dr. Reddy's Laboratories and Senores Pharmaceuticals Launch Ivermectin Tablets in US

                            Details : Stromectol-Generic (ivermectin) is a glutamate-gated chloride channel modulator, small molecule drug candidate, which is indicated for the treatment of patients with strongyloidiasis & onchocerciasis.

                            Product Name : Stromectol-Generic

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 26, 2024

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : Dr. Reddy\'s Laboratories

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Senores Pharmaceuticals

                            India arrow
                            BePharma
                            Not Confirmed

                            Senores Pharmaceuticals

                            India arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicardipine Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Senores Pharmaceuticals, Inc. Announces the Launch of Nicardipine Hydrochloride Capsules USP, 20 mg and 30 mg ...

                            Details : Nicardipine Hydrochloride Capsules is a calcium channel blocker indicated for the short-term treatment of hypertension when oral therapy is not feasible.

                            Product Name : Nicardipine Hydrochloride-Generic

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 25, 2023

                            Lead Product(s) : Nicardipine Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Senores Pharmaceuticals

                            India arrow
                            BePharma
                            Not Confirmed

                            Senores Pharmaceuticals

                            India arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Butalbital,Paracetamol,Caffeine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : Seton Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Seton Pharmaceuticals, LLC and Senores Pharmaceuticals, Inc. Launch Butalbital, Acetaminophen and Caffeine Cap...

                            Details : Butalbital, Acetaminophen and Caffeine Capsules USP, 50 mg/325 mg/40 mg, a therapeutic equivalent of reference listed drug Butalbital, Acetaminophen, and Caffeine capsules of Mayne Pharma, indicated for relief of symptom complex of tension (or muscle con...

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 17, 2022

                            Lead Product(s) : Butalbital,Paracetamol,Caffeine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Seton Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth